Insider Trading June 30, 2026 05:15 PM

908 Devices CEO Divests $25,433 in Pre-Arranged Stock Sale

Insider transaction follows strong six-month rally as the unprofitable semiconductor firm reports Q1 revenue growth but misses earnings expectations.

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
MASS

Kevin J. Knopp, President and Chief Executive Officer of 908 Devices Inc. (NASDAQ:MASS), executed a sale of 2,798 shares of the company's common stock on June 26, 2026. The transaction, valued at $25,433, was facilitated through a Rule 10b5-1 trading plan established by Mr. Knopp on May 20, 2025. The weighted average price for the sold shares was $9.09, with the transaction price ranging between $9.05 and $9.20 per share. This sale reduces Mr. Knopp's direct holdings, though he retains significant indirect ownership through a trust structure. The transaction occurs against a backdrop of recent financial reporting and stock market performance for 908 Devices.

908 Devices CEO Divests $25,433 in Pre-Arranged Stock Sale
MASS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • <strong>Insider Transaction Execution:</strong> CEO Kevin J. Knopp sold 2,798 shares via a pre-established Rule 10b5-1 plan, reducing direct holdings but maintaining significant indirect ownership through a trust structure.
  • <strong>Financial Performance Context:</strong> The sale coincides with Q1 2026 earnings that showed 14% revenue growth to $13.4 million, though the company reported an EPS miss of -113.33% with an EPS of -$0.32 against expectations of -$0.15.
  • <strong>Market Valuation Dynamics:</strong> The transaction occurs as the stock has gained 68% over the past six months, reaching a $329 million market cap, though analysts note the stock appears slightly overvalued relative to its Fair Value despite the company remaining unprofitable over the last twelve months.

Kevin J. Knopp, President and CEO of 908 Devices Inc. (NASDAQ:MASS), executed a transaction involving the sale of 2,798 shares of the company’s common stock on June 26, 2026. The total value of these sales reached $25,433. The shares were sold at prices ranging from $9.05 to $9.20, resulting in a weighted average price of $9.09 per share.

This sale was executed pursuant to a Rule 10b5-1 trading plan, which Mr. Knopp established on May 20, 2025. Following this transaction, Mr. Knopp directly holds 732,825 shares of 908 Devices common stock. He also indirectly holds an additional 541,223 shares through The Kevin J. Knopp Irrevocable Trust of 2018. While his brother-in-law serves as the trustee with sole voting and dispositive control over the trust’s securities, Mr. Knopp may be deemed the beneficial owner of these shares.

The insider sale comes as 908 Devices shares have shown strong momentum, with the stock posting a 68% return over the past six months. The company currently carries a market cap of $329 million, though it remains unprofitable with earnings per share of -$0.98 over the last twelve months. According to InvestingPro analysis, the stock appears slightly overvalued relative to its Fair Value. For deeper insights into MASS’s valuation and financial health, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities.

In other recent news, 908 Devices Inc. announced its Q1 2026 earnings, highlighting a 14% increase in revenue compared to the previous year, reaching $13.4 million. Despite this growth, the company reported an earnings per share (EPS) of -$0.32, which was below the anticipated -$0.15, resulting in an EPS surprise of -113.33%. This earnings miss did not deter the stock’s pre-market performance, which saw a rise, potentially influenced by strategic initiatives and the positive revenue figures. These developments are part of the company’s recent activities.

Risks

  • <strong>Profitability Concerns:</strong> 908 Devices remains unprofitable with an EPS of -$0.98 over the last twelve months, indicating ongoing operational challenges despite recent revenue growth.
  • <strong>Valuation Discrepancy:</strong> Analysis suggests the stock appears slightly overvalued relative to its Fair Value, which may present valuation risks for investors given the company's current financial trajectory.

More from Insider Trading

Windacre Partnership Reduces Stake in Perimeter Solutions with $195.6 Million Share Sale Jun 30, 2026 Climb Bio CEO Executes Pre-Arranged Share Sale Amid Clinical Progress and Corporate Governance Updates Jun 30, 2026 Lion Fund II Reduces El Pollo Loco Position Amid Strong Quarterly Results Jun 30, 2026 GALT Director Executes $150K Stock Sale Amid Clinical Milestones Jun 30, 2026 Paysign Executive Joan M. Herman Executes $800K+ Stock Sale Under Pre-Arranged Plan Jun 30, 2026